QC
SUPN icon

Quantedge Capital’s Supernus Pharmaceuticals SUPN Stock Holding History

Quantedge Capital’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-89,600
Closed -$4.45M – 79
2025
Q4 		$4.45M Sell
89,600
-31,500
-26% -$1.53M 2.12% 12
2025
Q3 		$5.79M Buy
+121,100
New +$4.88M 3.17% 8
2023
Q1 		– Sell
-18,900
Closed -$674K – 174
2022
Q4 		$674K Sell
18,900
-38,000
-67% -$1.32M 0.23% 93
2022
Q3 		$1.93M Buy
56,900
+35,600
+167% +$1.16M 0.59% 59
2022
Q2 		$616K Buy
+21,300
New +$610K 0.12% 156

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Quantedge Capital's SUPN Position: Q1 2026 in Review

Quantedge Capital sold out of Supernus Pharmaceuticals (SUPN) in Q1 2026, closing a stake of 89,600 shares — an estimated $4.45M sold.

Quantedge Capital first reported a position in SUPN in Q2 2022 and held it in 5 quarters. The position peaked at $5.79M in Q3 2025. 327 funds tracked by Wall St. Rank hold SUPN as of Q1 2026.

  • Quantedge Capital reported no remaining Supernus Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Quantedge Capital sold 89,600 Supernus Pharmaceuticals shares in Q1 2026, an estimated $4.45M.
  • Quantedge Capital first reported a position in Supernus Pharmaceuticals in Q2 2022 and held it in 5 quarters.
  • Quantedge Capital's Supernus Pharmaceuticals position peaked at $5.79M in Q3 2025.
  • 327 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2026.

Based on Quantedge Capital's 13F filing for Q1 2026, filed 12 May 2026.